About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

StemRIM(4599) Summary

4599
TSE Growth
StemRIM
287
JPY
-13
(-4.33%)
Apr 4, 3:30 pm JST
1.96
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
286.9
Apr 4, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.65
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
296 JPY 2.02 USD
Previous Close Apr 3
300 JPY 2.03 USD
High Apr 4, 9:01 am
298 JPY 2.03 USD
Low Apr 4, 2:07 pm
269 JPY 1.84 USD
Volume
846,900
Trading Value
0.24B JPY 1.65M USD
VWAP
284.5 JPY 1.95 USD
Minimum Trading Value
28,700 JPY 196 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
1,107
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Mid
1-Year Average
379
1-Year High Jul 9, 2024
3,762
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 0 2,442,100
Mar 21, 2025 0 2,409,400
Mar 14, 2025 0 2,405,500
Mar 7, 2025 0 2,391,800
Feb 28, 2025 0 2,400,300
Company Profile
StemRIM is a biotech venture originating from Osaka University, developing "regeneration-inducing medicine" that promotes self-tissue regeneration.
Sector
Pharmaceuticals
StemRIM is a research and development-based pharmaceutical venture founded at Osaka University. The company is engaged in the research and development of its proprietary "regeneration-inducing medicine" that promotes self-tissue regeneration and healing. This technology aims to achieve effects equivalent to regenerative medicine without using living cells, instead activating patients' own internal stem cells through compound administration to function broadly against various diseases. The company's lead pipeline product, redasemtide, is currently undergoing clinical trials for epidermolysis bullosa and acute cerebral infarction. Additionally, StemRIM is advancing research and development in a wide range of regeneration-inducing medical technologies, including novel peptides for systemic and local administration, therapeutic autologous cell collection devices, and stem cell gene therapy. Through these technologies, StemRIM aims to overcome the challenges of conventional regenerative medicine and realize safer and more effective treatment methods.